Rheumatology

The Three Major Manifestations of DADA2

At a Glance

DADA2 can appear in three overlapping patterns: blood-vessel inflammation and stroke risk, bone marrow problems causing anemia or low white blood cells, and immune deficiency with low antibodies. Many people have mixed or changing features, so care is individualized.

DADA2 is often described as a “multisystem” disorder because it can affect almost any part of the body. However, patients generally present with symptoms that fall into one of three major clinical patterns, or phenotypes. It is important to remember that these are not mutually exclusive diseases. They are overlapping ways the same genetic deficiency can show up, and many patients have a “mixed” presentation with symptoms from two or all three categories ^[1]^[2].

While one person may struggle primarily with skin rashes and fevers, another may have severe blood count issues. Furthermore, an individual’s phenotype can evolve over time.

1. The Vasculitic (Autoinflammatory) Phenotype

This is the most widely recognized way DADA2 presents. It is characterized by chronic, misdirected inflammation that attacks the blood vessels.

Key Features: Recurrent fevers, the signature lace-like skin rash (livedo racemosa), and inflammation in medium and small-sized blood vessels ^[3]^[4].
Major Risks: The greatest concern in this phenotype is the risk of ischemic stroke, which can occur even in very young children because of inflammation in the brain’s blood vessels ^[5]^[6].
Internal Involvement: This inflammation can also affect the gut (causing abdominal pain), the kidneys, and the peripheral nerves ^[3].

2. The Hematologic (Bone Marrow) Phenotype

In some patients, DADA2 primarily affects the bone marrow, where blood cells are made ^[1].

Key Features:
- Pure Red Cell Aplasia (PRCA): A condition where the body stops making red blood cells, leading to severe anemia and exhaustion ^[7].
- Neutropenia: A low count of neutrophils (a type of white blood cell), which increases the risk of bacterial infections and mouth sores ^[8].
- Bone Marrow Failure: In severe cases, the marrow may stop producing all types of blood cells ^[9].
Observation: Interestingly, some patients with this phenotype do not experience the prominent skin rashes or strokes seen in the vasculitic phenotype ^[7].

3. The Immunodeficiency Phenotype

The third clinical pattern involves the immune system’s ability to protect the body.

Key Features: Doctors often find low levels of antibodies (immunoglobulins) and low numbers of memory B cells, the cells responsible for remembering and fighting off germs ^[1]^[10].
Clinical Impact: While some patients have frequent or unusual infections, others have low antibody levels on paper but don’t actually get sick more often than normal ^[1]^[11].

Why Does DADA2 Look Different in Everyone?

Scientists believe the specific manifestations of DADA2 are partly influenced by an individual’s residual enzyme activity—how much the ADA2 enzyme is still able to work, even if it’s only a tiny bit ^[7]^[12].

Population Associations: In large observational cohorts, patients who retain a small amount of working enzyme activity tend to have the vasculitic phenotype. Conversely, patients with variants that result in near-zero activity are more frequently observed to develop the hematologic or immunodeficiency phenotypes early in life ^[7]^[13].
Not a Crystal Ball: It is crucial to understand that genotype and residual activity show population-level associations, but they cannot reliably predict an individual’s course. Even siblings with the exact same genetic variants can have very different symptoms, and a specific enzyme level should not be used alone to determine your prognosis or treatment ^[14]^[15].

How Phenotype Guides Your Care

Because DADA2 can present so differently, treatment plans are individualized based on your primary symptoms:

Vasculitis-Focused Care: If inflammation and stroke risk are the main concerns, TNF inhibitors are generally preferred as central, disease-modifying therapy ^[16]^[17].
Hematology/Immunology-Focused Care: If the main problem is severe or refractory bone marrow failure or profound immunodeficiency, a Hematopoietic Stem Cell Transplant (HSCT) may be considered by a specialized team ^[18]^[19]. For those with clinically meaningful antibody deficiencies or impaired vaccine responses, doctors may prescribe immunoglobulin replacement therapy ^[11].

Because these patterns overlap, your medical team will likely include specialists from rheumatology, hematology, and immunology to ensure every aspect of the disease is monitored ^[2]^[1].

Common questions in this guide

What are the three main ways DADA2 can affect the body?

DADA2 usually appears in a vasculitic or inflammatory pattern, a blood and bone marrow pattern, or an immune-deficiency pattern. These are overlapping patterns rather than separate diseases, and one person can have features of more than one.

What symptoms can occur with the vasculitic form of DADA2?

The vasculitic pattern may cause recurrent fevers, livedo racemosa, which is a lace-like skin rash, and inflammation in blood vessels. It can also affect the gut, kidneys, or nerves and can raise the risk of ischemic stroke, including in young children.

What blood problems are linked to the hematologic form of DADA2?

This pattern can cause pure red cell aplasia, which reduces red blood cell production and may lead to severe anemia and exhaustion. It can also cause neutropenia, mouth sores, bacterial infections, or bone marrow failure affecting several blood cell types.

Does DADA2 always cause frequent infections when antibody levels are low?

No. Some people with the immunodeficiency pattern have low antibody levels or low numbers of immune cells that remember germs and still do not get sick more often than usual. Doctors consider infection history, antibody testing, and vaccine responses when deciding whether immunoglobulin replacement is needed.

Can genetic results or ADA2 enzyme activity predict how my DADA2 will progress?

Residual enzyme activity and certain genetic variants are associated with different patterns in groups of patients, but they cannot reliably predict one person's symptoms or future course. Even siblings with the same variants may differ, so enzyme activity should not be used alone to choose treatment or estimate prognosis.

How is treatment chosen for the different DADA2 patterns?

Treatment is individualized to the main problems. TNF inhibitors are generally preferred when blood-vessel inflammation and stroke risk dominate. A hematopoietic stem cell transplant may be considered for severe or treatment-resistant bone marrow failure or profound immune deficiency, and immunoglobulin replacement may help when antibody deficiency or poor vaccine responses are clinically meaningful.

Get notified when new evidence is published on Deficiency of adenosine deaminase 2.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (19)

1
The Spectrum of the Deficiency of Adenosine Deaminase 2: An Observational Analysis of a 60 Patient Cohort.
Barron KS, Aksentijevich I, Deuitch NT, et al.
Frontiers in immunology 2021; (12()):811473 doi:10.3389/fimmu.2021.811473.
PMID: 35095905
2
Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus Statement.
Lee PY, Davidson BA, Abraham RS, et al.
JAMA network open 2023; (6(5)):e2315894 doi:10.1001/jamanetworkopen.2023.15894.
PMID: 37256629
3
[Multiple facets of ADA2 deficiency: Vasculitis, auto-inflammatory disease and immunodeficiency: A literature review of 135 cases from literature].
Fayand A, Sarrabay G, Belot A, et al.
La Revue de medecine interne 2018; (39(4)):297-306 doi:10.1016/j.revmed.2017.11.006.
PMID: 29273180
4
Testicular ischemia in deficiency of adenosine deaminase 2 (DADA2).
Clarke K, Campbell C, Omoyinmi E, et al.
Pediatric rheumatology online journal 2019; (17(1)):39 doi:10.1186/s12969-019-0334-5.
PMID: 31291964
5
Deficiency of Adenosine Deaminase 2: Clinical Manifestations, Diagnosis, and Treatment.
Grim A, Veiga KR, Saad N
Rheumatic diseases clinics of North America 2023; (49(4)):773-787 doi:10.1016/j.rdc.2023.06.004.
PMID: 37821195
6
Decoding neurovascular signatures: advanced imaging insights in DADA2-Related Cerebral Microangiopathy.
Zhou Y, Shen M, Jiang N, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (47(1)):18.
PMID: 41413740
7
Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2).
Lee PY, Kellner ES, Huang Y, et al.
The Journal of allergy and clinical immunology 2020; (145(6)):1664-1672.e10 doi:10.1016/j.jaci.2019.12.908.
PMID: 31945408
8
Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities.
Bulté D, Barzaghi F, Mesa-Nuñez C, et al.
The Journal of allergy and clinical immunology 2025; (155(2)):616-627.e8 doi:10.1016/j.jaci.2024.09.007.
PMID: 39284370
9
Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment.
Pinto B, Deo P, Sharma S, et al.
Clinical rheumatology 2021; (40(10)):3883-3896 doi:10.1007/s10067-021-05711-w.
PMID: 33791889
10
Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood.
Schepp J, Proietti M, Frede N, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(8)):1689-1700 doi:10.1002/art.40147.
PMID: 28493328
11
Clinical presentation of children with Deficiency of Adenosine deaminase 2: A case series.
Kisla Ekinci RM, Anlas O, Ozalp O
European journal of medical genetics 2022; (65(8)):104555 doi:10.1016/j.ejmg.2022.104555.
PMID: 35777620
12
Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants.
Yue J, LeSon CE, Rimland CA, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2026; (78(3)):734-742 doi:10.1002/art.43412.
PMID: 41147740
13
Adult-onset deficiency of adenosine deaminase 2-a case report and literature review.
Zhang B, Sun Y, Xu N, et al.
Clinical rheumatology 2021; (40(10)):4325-4339 doi:10.1007/s10067-021-05587-w.
PMID: 33638065
14
Phenotypic variability including Behçet's disease-like manifestations in DADA2 patients due to a homozygous c.973-2A>G splice site mutation.
van Well GTJ, Kant B, van Nistelrooij A, et al.
Clinical and experimental rheumatology 2019; (37 Suppl 121(6)):142-146.
PMID: 31856934
15
Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance.
Schnappauf O, Zhou Q, Moura NS, et al.
Journal of clinical immunology 2020; (40(6)):917-926 doi:10.1007/s10875-020-00817-3.
PMID: 32638197
16
Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2).
Cooray S, Omyinmi E, Hong Y, et al.
Rheumatology (Oxford, England) 2021; (60(9)):4373-4378 doi:10.1093/rheumatology/keaa837.
PMID: 33420503
17
The Many Faces of a Monogenic Autoinflammatory Disease: Adenosine Deaminase 2 Deficiency.
Kendall JL, Springer JM
Current rheumatology reports 2020; (22(10)):64 doi:10.1007/s11926-020-00944-1.
PMID: 32845415
18
Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Hashem H, Bucciol G, Ozen S, et al.
Journal of clinical immunology 2021; (41(7)):1633-1647 doi:10.1007/s10875-021-01098-0.
PMID: 34324127
19
Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2.
Hashem H, Kumar AR, Müller I, et al.
Blood 2017; (130(24)):2682-2688 doi:10.1182/blood-2017-07-798660.
PMID: 28974505

This page describes DADA2 phenotypes for informational purposes only and does not constitute medical advice. Your rheumatology, hematology, and immunology team should interpret symptoms and guide treatment for your situation.